Skip to main content
SpringerLink
Log in

New Target Sites for Treatment of Osteoporosis

  • Chapter
  • First Online:
Blue Biotechnology

Part of the book series: Progress in Molecular and Subcellular Biology ((MMB,volume 55))

Abstract

In the last few years, much progress has been achieved in the discovery of new drug target sites for treatment of osteoporotic disorders, one of the main challenging diseases with a large burden for the public health systems. Among these new agents promoting bone formation, shifting the impaired equilibrium between bone anabolism and bone catabolism in the direction of bone synthesis are inorganic polymers, in particular inorganic polyphosphates that show strong stimulatory effects on the expression of bone anabolic marker proteins and hydroxyapatite formation. The bone-forming activity of these polymers can even be enhanced by combination with certain small molecules like quercetin, or if given as functionally active particles with certain divalent cations like strontium ions even showing by itself biological activity. This chapter summarizes recent developments in the search and development of novel anti-osteoporotic agents, with a particular focus on therapeutic approaches based on the potential application of inorganic polymers and combinations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abramov AY, Fraley C, Diao CT, Winkfein R, Colicos MA, Duchen MR, French RJ, Pavlov E (2007) Targeted polyphosphatase expression alters mitochondrial metabolism and inhibits calcium-dependent cell death. Proc Natl Acad Sci USA 104:18091–18096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Adachi JD (1997) Corticosteroid-induced osteoporosis. Am J Med Sci 313:41–49

    CAS  PubMed  Google Scholar 

  • Adell T, Nefkens I, Müller WEG (2003) Polarity factor ‘Frizzled’ in the demosponge Suberites domuncula: identification, expression and localization of the receptor in the epithelium/pinacoderm. FEBS Lett 554:363–368

    Article  CAS  PubMed  Google Scholar 

  • Adell T, Thakur AN, Müller WEG (2007) Isolation and characterization of Wnt pathway-related genes from Porifera. Cell Biol Int 31:939–949

    Article  CAS  PubMed  Google Scholar 

  • Agholme F, Isaksson H, Kuhstoss S, Aspenberg P (2011) The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 48:988–996

    Article  CAS  PubMed  Google Scholar 

  • Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19:557–566

    Article  CAS  PubMed  Google Scholar 

  • Ahn V, Chu M, Choi H, Tran D, Abo A, Weis W (2011) Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Dev Cell 21:862–873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Akune T (2004) The role of insuline receptor substrates in bone metabolism. Clin Calcium 14:289–292

    CAS  PubMed  Google Scholar 

  • Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E (2010) The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol 72:752–757

    Article  CAS  Google Scholar 

  • Aspenberg P (2006) Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf 5:743–745

    Article  CAS  PubMed  Google Scholar 

  • Atchison D, Harding P, Beierwaltes W (2011) Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension 58:604–610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Austin K, Markovic MA, Brubaker PL (2016) Current and potential therapeutic targets of glucagon-like peptide-2. Curr Opin Pharmacol 31:13–18

    Article  CAS  PubMed  Google Scholar 

  • Balan G, Bauman J, Bhattacharya S, Castrodad M, Healy DR, Herr M, Humphries P, Jennings S, Kalgutkar AS, Kapinos B, Khot V, Lazarra K, Li M, Li Y, Neagu C, Oliver R, Piotrowski DW, Price D, Qi H, Simmons HA, Southers J, Wei L, Zhang Y, Paralkar VM (2009) The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett 19:3328–3332

    Article  CAS  PubMed  Google Scholar 

  • Barille S, Pellat-Deceunynck C, Bataille R, Amiot M (1996) Ectopic secretion of osteocalcin, the major non-collagenous bone protein, by the myeloma cell line NCI-H929. J Bone Miner Res 11:466–471

    Article  CAS  PubMed  Google Scholar 

  • Baron R, Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status and perspectives. J Clin Endocrinol Metab 97:311–325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179–192

    Article  CAS  PubMed  Google Scholar 

  • Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC (2016) The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther 7:15. doi:10.1186/s13287-016-0372-6

    Article  Google Scholar 

  • Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 1:2–13

    Article  CAS  Google Scholar 

  • Bhagwat S, Haytowitz DB, Holden JM (2011) USDA database for the flavonoid content of selected foods; release 3. US Department of Agriculture, Beltsville

    Google Scholar 

  • Blake G, Fogelman I (2007) Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 10:102–110

    Article  PubMed  Google Scholar 

  • Blick SK, Dhillon S, Keam SJ (2009) Spotlight on teriparatide in osteoporosis. BioDrugs 23:197–199

    Article  PubMed  Google Scholar 

  • Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947

    PubMed  Google Scholar 

  • Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellström D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bonnelye EA, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129–138

    Article  CAS  PubMed  Google Scholar 

  • Boudin E, Fijalkowski I, Piters E, Van Hul W (2013) The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin Arthritis Rheum 43:220–240

    Article  CAS  PubMed  Google Scholar 

  • Branca F (2003) Dietary phyto-oestrogens and bone health. Proc Nutr Soc 62:877–887

    Article  CAS  PubMed  Google Scholar 

  • Bringhurst F (2002) PTH receptors and apoptosis in osteocytes. J Musculoskelet Neuronal Interact 2:245–251

    CAS  PubMed  Google Scholar 

  • Brown E (2007) The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 45:139–167

    Article  CAS  PubMed  Google Scholar 

  • Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297

    CAS  PubMed  Google Scholar 

  • Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bullamore JR, Wilkinson R, Gallagher JC, Nordin BE, Marshall DH (1970) Effect of age on calcium absorption. Lancet 2(7672):535–537

    Google Scholar 

  • Butler JS, Murray DW, Hurson CJ, O’Brien J, Doran PP, O’Bryne JM (2011) The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res 29:414–418

    Article  PubMed  Google Scholar 

  • Cabal A, Mehta K, Ross DS, Shrestha RP, Comisar W, Denker A, Pai SM, Ishikawa T (2013) A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. Bone Miner Res 28:1830–1836

    Article  CAS  Google Scholar 

  • Canalis E (2013) Wnt signaling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 9:575–583

    Article  CAS  PubMed  Google Scholar 

  • Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ (1996) The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517–523

    Article  CAS  PubMed  Google Scholar 

  • Choi H, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4:e7930

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D’Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R (2011) Sirt1 is a regulator of bone mass and a repressor of SOST encoding for sclerostin, a bone formation inhibitor. Endocrinology 152:4514–4524

    Google Scholar 

  • Compton JT, Lee FY (2014) A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am 96:1659–1668

    Article  PubMed  PubMed Central  Google Scholar 

  • Cook F, Mumm S, Whyte M, Wenkert D (2014) Pregnancy-associated osteoporosis with a heterozygous deactivating LDL receptor-related protein 5 (LRP5) mutation and a homozygous methylenetetrahydrofolate reductase (MTHFR) polymorphism. J Bone Miner Res 29:922–928

    Article  CAS  PubMed  Google Scholar 

  • Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7:447–456

    Article  CAS  PubMed  Google Scholar 

  • Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial FREEDOM (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  • Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696

    Google Scholar 

  • Dalle Carbonare L, Innamorati G, Valenti MT (2012) Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell Rev 8:891–897

    Article  CAS  PubMed  Google Scholar 

  • Davidge Pitts CJ, Kearns A (2011) Update on Medications with adverse skeletal effects. Mayo Clin Proc 86:338–343

    Article  PubMed  Google Scholar 

  • Deal C (2009) Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 5:20–27

    Article  CAS  PubMed  Google Scholar 

  • Devogelaer J (2000) Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 12:331–335

    Article  CAS  PubMed  Google Scholar 

  • Di Carlo G, Mascolo N, Izzo AA, Capasso F (1999) Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 65:337–353

    Article  PubMed  Google Scholar 

  • Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163

    Article  CAS  PubMed  Google Scholar 

  • Drozen MS, Foley JF (2007) Gras notification: alpha-glycosyl isoquercitrin. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-foods-gen/docu-ments/document/ucm269110.pdf

  • Dunnick JK, Hailey JR (1992) Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam Appl Toxicol 19:423–431

    Article  CAS  PubMed  Google Scholar 

  • Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three year continued therapy and resolution effect. J Bone Miner Res 26:242–251

    Article  CAS  PubMed  Google Scholar 

  • Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV, Marvell T, Monnell TE, Ucran JA, Pearsall AE, Khanzode D, Kumar R, Underwood KW, Roberts B, Seehra J, Bouxsein ML (2010) Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46:64–71

    Article  CAS  PubMed  Google Scholar 

  • Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4:30–34

    Article  CAS  PubMed  Google Scholar 

  • Fleisch H, Straumann F, Schenk R, Bisaz S, Allgöwer M (1966) Effect of condensed phosphates on calcification of chick embryo femurs in tissue culture. Am J Physiol 211:821–825

    CAS  PubMed  Google Scholar 

  • Fraher LJ, Avram R, Watson PH, Hendy GN, Henderson JE, Chong KL, Goltzman D, Morley P, Willick GE, Whitfield JF, Hodsman AB (1999) Comparison of the biochemical responses to human parathyroid hormone-(1–31)NH2 and hPTH-(1–34) in healthy humans. J Clin Endocrinol Metab 84:2739–2743

    CAS  PubMed  Google Scholar 

  • Fraser W, Ahmad A, Vora J (2004) The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis. Curr Opin Nephrol Hypertens 13:437–444

    Article  CAS  PubMed  Google Scholar 

  • Fromigue O, Hay E, Barbara A, Petrel C, Traiffort E, Ruat M, Marie PJ (2009) Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med 13:2189–2199

    Article  PubMed  Google Scholar 

  • Fujiwara M, Kubota T, Wang W, Ohata Y, Miura K, Kitaoka T, Okuzaki D, Namba N, Michigami T, Kitabatake Y, Ozono K (2016) Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2. Bone 85:91–98

    Article  CAS  PubMed  Google Scholar 

  • Gallagher JC, Tella SH (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170

    Article  PubMed  CAS  Google Scholar 

  • Gardner MJ, Demetrakopoulos D, Shindle MK, Griffith MH, Lane JM (2006) Osteoporosis and skeletal fractures. HSS J 2:62–69

    Article  PubMed  PubMed Central  Google Scholar 

  • Garnero P (2008) Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 12:157–170

    Article  CAS  PubMed  Google Scholar 

  • Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti M, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE (2012) Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97:3744–3750

    Article  CAS  PubMed  Google Scholar 

  • Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923–928

    Article  CAS  PubMed  Google Scholar 

  • Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, Loots GG, Yellowley CE (2010) Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem 110:457–467

    CAS  PubMed  PubMed Central  Google Scholar 

  • Glantschnig H, Hampton R, Lu P, Zhao J, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F (2010) Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 285:40135–40147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Glantschnig H, Scott K, Hampton R, Wei N, Mccracken P, Nantermet P, Zhao JZ, Vitelli S, Huang L, Haytko P, Lu P, Fisher JE, Sandhu P, Cook J, Williams D, Strohl W, Flores O, Kimmel D, Wang F, An Z (2011) A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 338:568–578

    Google Scholar 

  • Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595–1604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gu Z, Zhang X, Li L, Wang Q, Yu X, Feng T (2013) Acceleration of segmental bone regeneration in a rabbit model by strontium-doped calcium polyphosphate scaffold through stimulating VEGF and bFGF secretion from osteoblasts. Mater Sci Eng C 33:274–281

    Article  CAS  Google Scholar 

  • Guder C, Pinho S, Nacak TG, Schmidt HA, Hobmayer B, Niehrs C, Holstein TW (2006) An ancient Wnt-Dickkopf antagonism in Hydra. Development 133:901–911

    Article  CAS  PubMed  Google Scholar 

  • Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, Eastell R (2010) Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 25:463–471

    Article  CAS  PubMed  Google Scholar 

  • Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J (2010) Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 69:2152–2159

    Article  CAS  PubMed  Google Scholar 

  • Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ (2004) Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 34:140–147

    Article  CAS  PubMed  Google Scholar 

  • Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C (2009) Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45:833–842

    Article  CAS  PubMed  Google Scholar 

  • Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA (2013) Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis. Bone 53:160–166

    Article  CAS  PubMed  Google Scholar 

  • Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millan JL (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99:9445–9449

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoeppner L, Secreto F, Westendorf J (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485–496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12

    Article  CAS  PubMed  Google Scholar 

  • Hopkins RB, Tarride JE, Leslie WD, Metge C, Lix LM, Morin S, Finlayson G, Azimaee M, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Thabane L (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24:581–593

    Article  CAS  PubMed  Google Scholar 

  • Itoh T, Takeda S, Akao Y (2010) MicroRNA-208 modulates BMP-2-stimulated mouse preosteoblast differentiation by directly targeting V-ets erythroblastosis virus E26 oncogene homolog 1. J Biol Chem 285:27745–27752

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Itoh T, Ando M, Tsukamasa Y, Akao Y (2012) Expression of BMP-2 and Ets1 in BMP-2- stimulated mouse pre-osteoblast differentiation is regulated by microRNA-370. FEBS Lett 586:1693–1701

    Article  CAS  PubMed  Google Scholar 

  • Jang WG, Kim EJ, Kim DK, Ryoo HM, Lee KB, Kim SH, Choi HS, Koh JT (2012) BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. J Biol Chem 287:905–915

    Article  CAS  PubMed  Google Scholar 

  • John MR, Widler L, Gamse R, Buhl T, Seuwen K, Breitenstein W, Bruin GJ, Belleli R, Klickstein LB, Kneissel M (2011) ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 49:233–241

    Article  CAS  PubMed  Google Scholar 

  • Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S, Goding JW, Sano K, Millan JL, Terkeltaub R (2000) Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 279:R1365–R1377

    CAS  PubMed  Google Scholar 

  • Kalinova J, Vrchotova N (2009) Level of catechin, myricetin, quercetin and isoquercitrin in buckwheat (Fagopyrum esculentum Moench), changes of their levels during vegetation and their effect on the growth of selected weeds. J Agric Food Chem 57:2719–2725

    Article  CAS  PubMed  Google Scholar 

  • Kanis JA (1994) WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381

    Article  CAS  PubMed  Google Scholar 

  • Khan A, Khan A (2006) Anabolic agents: a new chapter in the management of osteoporosis. J Obstet Gynaecol Can 28:136–141

    Article  PubMed  Google Scholar 

  • Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491

    Google Scholar 

  • Kim HJ, Kim SH (2010) Tanshinone IIA enhances BMP-2-stimulated commitment of C2C12 cells into osteoblasts via p38 activation. Amino Acids 39:1217–1226

    Article  CAS  PubMed  Google Scholar 

  • Kim YJ, Bae YC, Suh KT, Jung JS (2006) Quercetin, a flavonoid, inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells. Biochem Pharmacol 72:1268–1278

    Article  CAS  PubMed  Google Scholar 

  • Kim JB, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, Helms JA (2007) Bone regeneration is regulated by wnt signaling. J Bone Miner Res 22:1913–1923

    Article  CAS  PubMed  Google Scholar 

  • Kim JH, Liu X, Wang J, Chen X, Zhang H, Kim SH, Cui J, Li R, Zhang W, Kong Y, Zhang J, Shui W, Lamplot J, Rogers MR, Zhao C, Wang N, Rajan P, Tomal J, Statz J, Wu N, Luu HH, Haydon RC, He TC (2013) Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis 5:13–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kong WN (2012) Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging 12:235–247

    Google Scholar 

  • Kornberg A, Rao NN, Ault-Riche D (1999) Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 68:89–125

    Article  CAS  PubMed  Google Scholar 

  • Košinová P, Berka K, Wykes M, Otyepka M, Trouillas P (2012) Positioning of antioxidant quercetin and its metabolites in lipid bilayer membranes: implication for their lipid-peroxidation inhibition. J Phys Chem B 116:1309–1318

    Article  PubMed  CAS  Google Scholar 

  • Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL (2006) Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21:910–920

    Article  CAS  PubMed  Google Scholar 

  • Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup GB, Vaden VR, Haley H, Fox J, DelMar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA (2010) An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 46:534–542

    Article  CAS  PubMed  Google Scholar 

  • Lane NE (2006) Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194(Suppl):S3–S11

    Article  CAS  PubMed  Google Scholar 

  • Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A (2012) Danacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251–2258

    Google Scholar 

  • Lee D, Kim H, Ku S, Kim S, Choi Y, Kim J (2010) Association between polymorphisms in Wnt signaling pathway genes and bone mineral density in postmenopausal Korean women. Menopause 17:1064–1070

    Article  PubMed  Google Scholar 

  • Leibbrandt A, Penninger JM (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 1143:123–150

    Article  CAS  PubMed  Google Scholar 

  • Lengfeld T, Watanabe H, Simakov O, Lindgens D, Gee L, Law L, Schmidt HA, Ozbek S, Bode H, Holstein TW (2009) Multiple Wnts are involved in Hydra organizer formation and regeneration. Dev Biol 330:186–199

    Article  CAS  PubMed  Google Scholar 

  • Lewiecki E (2013) Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther 13:183–196

    Article  CAS  PubMed  Google Scholar 

  • Leyhausen G, Lorenz B, Zhu H, Geurtsen W, Bohnensack R, Müller WEG, Schröder HC (1998) Inorganic polyphosphate in human osteoblast-like cells. J Bone Miner Res 13:803–812

    Article  CAS  PubMed  Google Scholar 

  • Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754–766

    Article  CAS  PubMed  Google Scholar 

  • Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588

    Article  CAS  PubMed  Google Scholar 

  • Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647–2656

    Article  PubMed  CAS  Google Scholar 

  • Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavallee J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG (2011) Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26:2610–2621

    Article  CAS  PubMed  Google Scholar 

  • Lim V, Clarke B (2012) New therapeutic targets for osteoporosis: beyond denosumab. Maturitas 73:269–272

    Article  CAS  PubMed  Google Scholar 

  • Lindsay R (1996) The menopause and osteoporosis. Obstet Gynecol 87:16S–19S

    Article  CAS  PubMed  Google Scholar 

  • Lorenz B, Schröder HC (2001) Mammalian intestinal alkaline phosphatase acts as highly active exopolyphosphatase. Biochim Biophys Acta 1547:254–261

    Article  CAS  PubMed  Google Scholar 

  • Lorenz B, Münkner J, Oliveira MP, Kuusksalu A, Leitão JM, Müller WEG, Schröder HC (1997) Changes in metabolism of inorganic polyphosphate in rat tissues and human cells during development and apoptosis. Biochim Biophys Acta 1335:51–60

    Article  CAS  PubMed  Google Scholar 

  • MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213

    Article  PubMed  Google Scholar 

  • Maeda A, Okazaki M, Baron DM, Dean T, Khatri A, Mahon M, Segawa H, Abou-Samra AB, Jüppner H, Bloch KD, Potts JT Jr, Gardella TJ (2013) Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci USA 110:5864–5869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malinauskas T, Jones EY (2014) Extracellular modulators of Wnt signalling. Curr Opin Struct Biol 29:77–84

    Article  CAS  PubMed  Google Scholar 

  • Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 417:664–667

    Article  CAS  PubMed  Google Scholar 

  • Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385–2395

    Article  CAS  PubMed  Google Scholar 

  • Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 18(Suppl1):S11–S15

    Article  PubMed  Google Scholar 

  • McColm J, Hu L, Womack T, Tang CC, Chiang AY (2014) Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29:935–943

    Article  CAS  PubMed  Google Scholar 

  • Mezesova L, Bartekova M, Javorkova V, Vlkovicova J, Breier A, Vrbjar N (2010) Effect of quercetin on kinetic properties of renal Na, K-ATPase in normotensive and hypertensive rats. J Physiol Pharmacol 61:593–598

    CAS  PubMed  Google Scholar 

  • Miller PD, Chines AA, Christiansen C (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535

    Article  CAS  PubMed  Google Scholar 

  • Minisola G, Iuliano A, Prevete I (2014) Emerging therapies for osteoporosis. Reumatismo 66:112–124

    Article  CAS  PubMed  Google Scholar 

  • Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R (2004) Src kinase activity is essential for osteoclast function. J Biol Chem 279:17660–17666

    Article  CAS  PubMed  Google Scholar 

  • Morrissey JH, Choi SH, Smith SA (2012) Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 119:5972–5979

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mosley J (2000) Osteoporosis and bone functional adaptation: mechanobiological regulation of bone architecture in growing and adult bone, a review. J Rehabil Res Dev 37:189–199

    CAS  PubMed  Google Scholar 

  • Müller WEG, Wang XH, Diehl-Seifert B, Kropf K, Schloßmacher U, Lieberwirth I, Glasser G, Wiens M, Schröder HC (2011) Inorganic polymeric phosphate/polyphosphate as an inducer of alkaline phosphatase and a modulator of intracellular Ca2+ level in osteoblasts (SaOS-2 cells) in vitro. Acta Biomater 7:2661–2671

    Article  PubMed  CAS  Google Scholar 

  • Müller WEG, Schröder HC, Schlossmacher U, Grebenjuk VA, Ushijima H, Wang XH (2013a) Induction of carbonic anhydrase in SaOS-2 cells, exposed to bicarbonate and consequences for calcium phosphate crystal formation. Biomaterials 34:8671–8680

    Article  PubMed  CAS  Google Scholar 

  • Müller WEG, Wang XH, Grebenjuk V, Diehl-Seifert B, Steffen R, Schloßmacher U, Trautwein A, Neumann S, Schröder HC (2013b) Silica as a morphogenetically active inorganic polymer: effect on the BMP-2-dependent and RUNX2-independent pathway in osteoblast-like SaOS-2 cells. Biomater Sci 1:669–678

    Article  CAS  Google Scholar 

  • Müller WEG, Tolba E, Feng QL, Schröder HC, Markl JS, Kokkinopoulou M, Wang XH (2015a) Amorphous Ca2+ polyphosphate nanoparticles regulate the ATP level in bone-like SaOS-2 cells. J Cell Sci 128:2202–2207

    Article  PubMed  CAS  Google Scholar 

  • Müller WEG, Tolba E, Schröder HC, Wang XH (2015b) Polyphosphate: a morphogenetically active implant material serving as metabolic fuel for bone regeneration. Macromol Biosci 15:1182–1197

    Article  PubMed  CAS  Google Scholar 

  • Müller WEG, Tolba E, Schröder HC, Wang SF, Glaßer G, Muñoz-Espí R, Link T, Wang XH (2015c) A new polyphosphate calcium material with morphogenetic activity. Mater Lett 148:163–166

    Article  CAS  Google Scholar 

  • Müller WEG, Schröder HC, Tolba E, Neufurth M, Diehl-Seifert B, Wang XH (2016a) Mineralization of bone-related SaOS-2 cells under physiological hypoxic conditions. FEBS J 283:74–87

    Article  PubMed  CAS  Google Scholar 

  • Müller WEG, Tolba E, Neufurth M, Wang SF, Ackermann M, Feng QL, Schröder HC, Wang XH (2016b) Fabrication of amorphous strontium polyphosphate microparticles that induce mineralization of bone cells in vitro and in vivo. Submitted

    Google Scholar 

  • Murakami T, Saito A, Hino S, Kondo S, Kanemoto S, Chihara K, Sekiya H, Tsumagari K, Ochiai K, Yoshinaga K, Saitoh M, Nishimura R, Yoneda T, Kou I, Furuichi T, Ikegawa S, Ikawa M, Okabe M, Wanaka A, Imaizumi K (2009) Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat Cell Biol 11:1205–1211

    Article  CAS  PubMed  Google Scholar 

  • Murphy MG, Cerchio S, Stoch A, Gottesdiener K, Wu M, Recker R (2005) Effect of L000845704, an αvβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 90:2022–2028

    Article  CAS  PubMed  Google Scholar 

  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  • Nemeth EF (2002) The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol 29:15–21

    Article  CAS  PubMed  Google Scholar 

  • Nemeth E (2004) Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium 35:283–289

    Article  CAS  PubMed  Google Scholar 

  • Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY (2008) Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv Ther 25:1235–1256

    Article  CAS  PubMed  Google Scholar 

  • Niedźwiedzki T, Filipowska J (2015) Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system. J Mol Endocrinol 55:R23–R36

    Article  PubMed  CAS  Google Scholar 

  • Nielsen SP (2004) The biological role of strontium. Bone 35:583–588

    Article  CAS  Google Scholar 

  • Notoya M, Tsukamoto Y, Nishimura H, Woo JT, Nagai K, Lee IS, Hagiwara H (2004) Quercetin, a flavonoid, inhibits the proliferation, differentiation, and mineralization of osteoblasts in vitro. Eur J Pharmacol 485:89–96

    Article  CAS  PubMed  Google Scholar 

  • Oh WJ, Endale M, Park SC, Cho JY, Rhee MH (2012) Dual roles of quercetin in platelets: phosphoinositide-3-kinase and MAP kinases inhibition, and cAMP-dependent vasodilator-stimulated phosphoprotein stimulation. Evid Based Complement Alternat Med 2012:485262. doi:10.1155/2012/485262

    PubMed  PubMed Central  Google Scholar 

  • Okuducu AF, Zils U, Michaelis SA, Mawrin C, von Deimling A (2006) Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and ΜMP-9. Cancer 107:1365–1372

    Article  CAS  PubMed  Google Scholar 

  • Omelon SJ, Grynpas MD (2008) Relationships between polyphosphate chemistry, biochemistry and apatite biomineralization. Chem Rev 108:4694–4715

    Article  CAS  PubMed  Google Scholar 

  • Omelon S, Georgiou J, Henneman ZJ, Wise LM, Sukhu B, Hunt T, Wynnyckyj C, Holmyard D, Bielecki R, Grynpas MD (2009) Control of vertebrate skeletal mineralization by polyphosphates. PLoS ONE 4:e5634. doi:10.1371/journal.pone.0005634

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner 26:1012–1021

    Article  CAS  Google Scholar 

  • Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043–1051

    Article  CAS  PubMed  Google Scholar 

  • Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26

    Article  CAS  PubMed  Google Scholar 

  • Paulke A, Eckert GP, Schubert-Zsilavecz M, Wurglics M (2012) Isoquercitrin provides better bioavailability than quercetin: comparison of quercetin metabolites in body tissue and brain sections after six days administration of isoquercitrin and quercetin. Pharmazie 67:991–996

    CAS  PubMed  Google Scholar 

  • Pavlov E, Aschar-Sobbi R, Campanella M, Turner RJ, Gómez-García MR, Abramov AY (2010) Inorganic polyphosphate and energy metabolism in mammalian cells. J Biol Chem 285:9420–9428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW (2011) The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. Bone 49:1290–1298

    Article  CAS  PubMed  Google Scholar 

  • Pereira M, Jeyabalan J, Jørgensen CS, Hopkinson M, Al-Jazzar A, Roux JP, Chavassieux P, Orriss IR, Cleasby ME, Chenu C (2015) Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 81:459–467

    Article  CAS  PubMed  Google Scholar 

  • Prouillet C, Mazière JC, Mazière C, Wattel A, Brazier M, Kamel S (2004) Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol 67:1307–1313

    Article  CAS  PubMed  Google Scholar 

  • Qin DW, Gu Z, Dai L, Ji C (2013) Protective effects of gallium, germanium, and strontium against ovariectomized osteoporosis in rats. Biol Trace Elem Res 153:350–354

    Article  CAS  PubMed  Google Scholar 

  • Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318–3325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30:216–224

    Article  CAS  PubMed  Google Scholar 

  • Reginster JY, Brandi ML, Cannata-Andía J, Cooper C, Cortet B, Feron JM, Genant H, Palacios S, Ringe JD, Rizzoli R (2015) The position of strontium ranelate in today’s management of osteoporosis. Osteoporos Int 26:1667–1671

    Article  CAS  PubMed  Google Scholar 

  • Reid IR (2008) Anti-resorptive therapies for osteoporosis. Semin Cell Dev Biol 19:473–478

    Article  CAS  PubMed  Google Scholar 

  • Riccardi D (2012) Antagonizing the calcium-sensing receptor: towards new bone anabolics? Curr Mol Pharmacol 5:182–188

    Article  CAS  PubMed  Google Scholar 

  • Riggs BL, Khosla S, Melton LJ (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773

    Article  CAS  PubMed  Google Scholar 

  • Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841–847

    Article  CAS  PubMed  Google Scholar 

  • Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875

    Article  CAS  PubMed  Google Scholar 

  • Rochefort GY (2014) The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskel Dis 6:79–91

    Article  CAS  Google Scholar 

  • Rodan SB, Duong LT (2008) Cathepsin K—a new molecular target for osteoporosis. Bonekey Osteovision 5:16–24

    Google Scholar 

  • Römer P, Behr M, Proff P, Faltermeier A, Reicheneder C (2011) Effect of strontium on human Runx2+/- osteoblasts from a patient with cleidocranial dysplasia. Eur J Pharmacol 654:195–199

    Article  PubMed  CAS  Google Scholar 

  • Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66–S80

    Article  PubMed  Google Scholar 

  • Rybchyn MS, Slater M, Conigrave AD, Mason RS (2011) An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J Biol Chem 286:23771–23779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018

    Article  CAS  PubMed  Google Scholar 

  • Sassi N, Laadhar L, Allouche M, Zandieh-Doulabi B, Hamdoun M, Klein-Nulend J, Makni S, Sellami S (2013) The roles of canonical and non-canonical Wnt signaling in human de-differentiated articular chondrocytes. Biotech Histochem 13:384–392

    Google Scholar 

  • Schnatz P, Marakovits K, O’Sullivan D (2010) Assessment of postmenopausal women and significant risk factors for osteoporosis. Obstet Gynecol Surv 65:591–596

    Article  PubMed  Google Scholar 

  • Scholtysek C, Katzenbeisser J, Fu H, Uderhardt S, Ipseiz N, Stoll C, Zaiss MM, Stock M, Donhauser L, Böhm C, Kleyer A, Hess A, Engelke K, David JP, Djouad F, Tuckermann JP, Desvergne B, Schett G, Krönke G (2013) PPARβ/δ governs Wnt signaling and bone turnover. Nat Med 19:608–613

    Article  CAS  PubMed  Google Scholar 

  • Schröder HC, Wiens M, Wang XH, Schloßmacher U, Müller WEG (2011) Biosilica-based strategies for treatment of osteoporosis and other bone diseases. Prog Mol Subcell Biol 52:283–312

    Article  PubMed  CAS  Google Scholar 

  • Selenge E, Murata T, Kobayashi K, Batkhuu J, Yoshizaki F (2013) Flavone tetraglycosides and benzyl alcohol glycosides from the Mongolian medicinal plant Dracocephalum ruyschiana. J Nat Prod 76:186–193

    Article  CAS  PubMed  Google Scholar 

  • Shah AD, Shoback D, Lewiecki EM (2015) Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health 7:565–580

    CAS  PubMed  PubMed Central  Google Scholar 

  • Shevde NK, Bendixen AC, Dienger KM, Pike JW (2000) Estrogens suppress RANK ligandinduced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 97:7829–7834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319

    Article  CAS  PubMed  Google Scholar 

  • Singer A, Grauer A (2010) Denosumab for the management of postmenopausal osteoporosis. Postgrad Med 122:176–187

    Article  PubMed  Google Scholar 

  • Son YO, Kook SH, Choi KC, Jang YS, Jeon YM, Kim JG, Lee KY, Kim J, Chung MS, Chung GH, Lee JC (2006) Quercetin, a bioflavonoid, accelerates TNF-alpha-induced growth inhibition and apoptosis in MC3T3-E1 osteoblastic cells. Eur J Pharmacol 529:24–32

    Article  CAS  PubMed  Google Scholar 

  • Stoch SA, Zajic S, Stone J, Miller DL, Van Dick K, Gutierrez MJ (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthly postmenopausal women: two double blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175–182

    Article  CAS  PubMed  Google Scholar 

  • Sun G, Guo T, Chen Y, Xu B, Guo JH, Zhao J (2013) Significant pathways detection in osteoporosis based on the bibliometric network. Eur Rev Med Pharmacol Sci 17:1–7

    CAS  PubMed  Google Scholar 

  • Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666

    Article  CAS  PubMed  Google Scholar 

  • Taranta A, Brama M, Teti A, De luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S (2002) The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30:368–376

    Google Scholar 

  • Taxel P, Kenny A (2000) Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone 2:11–21

    Article  CAS  PubMed  Google Scholar 

  • Trivedi R, Mithal A, Chattopadhyay N (2008) Recent updates on the calcium-sensing receptor as a drug target. Curr Med Chem 15:178–186

    Article  CAS  PubMed  Google Scholar 

  • Van Bezooijen R, Ten Dijke P, Papapoulos S, Lowik C (2005) SOST/sclerostin, an osteocytederived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319–327

    Article  PubMed  CAS  Google Scholar 

  • Van der Lee MM, Verkaar F, Wat JW, van Offenbeek J, Timmerman M, Voorneveld L, van Lith LH, Zaman GJ (2013) Beta-arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor. Cell Signal 25:527–538

    Article  PubMed  CAS  Google Scholar 

  • Vilardaga JP, Romero G, Friedman PA, Gardella TJ (2011) Molecular basis of parathyroid eceptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci 68:1–13

    Article  CAS  PubMed  Google Scholar 

  • Wan Y, Chong LW, Evans RM (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13:1496–1503

    Article  CAS  PubMed  Google Scholar 

  • Wang FS, Lin CL, Chen YJ, Wang CJ, Yang KD, Huang YT, Sun YC, Huang HC (2005) Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 146:2415–2423

    Article  CAS  PubMed  Google Scholar 

  • Wang Y, Liu Y, Rowe D (2007) Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am J Physiol Endocrinol Metab 292:E594–E603

    Article  CAS  PubMed  Google Scholar 

  • Wang FS, Ko JY, Weng LH, Yeh DW, Ke HJ, Wu SL (2009) Inhibition of glycogen synthase kinase 3β attenuates glucocorticoid induced bone loss. Life Sci 85:685–692

    Article  CAS  PubMed  Google Scholar 

  • Wang XH, Schröder HC, Wiens M, Ushijima H, Müller WEG (2012) Bio-silica and bio-polyphosphate: applications in biomedicine (bone formation). Curr Opin Biotechnol 23:570–578

    Article  CAS  PubMed  Google Scholar 

  • Wang XH, Schröder HC, Diehl-Seifert B, Kropf K, Schlossmacher U, Wiens M, Müller WEG (2013) Dual effect of inorganic polymeric phosphate/polyphosphate on osteoblasts and osteoclasts in vitro. J Tissue Engin Regen Med 7:767–776

    CAS  Google Scholar 

  • Wang XH, Schröder HC, Grebenjuk V, Diehl-Seifert B, Mailänder V, Steffen R, Schloßmacher U, Müller WEG (2014a) The marine sponge-derived inorganic polymers, biosilica and polyphosphate, as morphogenetically active matrices/scaffolds for differentiation of human multipotent stromal cells: potential application in 3D printing and distraction osteogenesis. Mar Drugs 12:1131–1147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang XH, Schröder HC, Müller WEG (2014b) Enzymatically synthesized inorganic polymers as morphogenetically active bone scaffolds: application in regenerative medicine. Int Rev Cell Mol Biol 313:27–77

    Article  PubMed  Google Scholar 

  • Wang XH, Schröder HC, Feng Q, Diehl-Seifert B, Grebenjuk VA, Müller WEG (2014c) Isoquercitrin and polyphosphate co-enhance mineralization of human osteoblast-like SaOS-2 cells via separate activation of two RUNX2 cofactors AFT6 and Ets1. Biochem Pharmacol 89:413–421

    Article  CAS  PubMed  Google Scholar 

  • Wang XH, Schröder HC, Schlossmacher U, Neufurth M, Feng Q, Diehl-Seifert B, Müller WEG (2014d) Modulation of the initial mineralization process of SaOS-2 cells by carbonic anhydrase activators and polyphosphate. Calcif Tissue Int 94:495–509

    Article  CAS  PubMed  Google Scholar 

  • Wang XH, Huang J, Wang K, Neufurth M, Schröder HC, Wang SF, Müller WEG (2016a) The morphogenetically active polymer, inorganic polyphosphate complexed with GdCl3, as an inducer of hydroxyapatite formation in vitro. Biochem Pharmacol 102:97–106

    Article  CAS  PubMed  Google Scholar 

  • Wang XH, Schröder HC, Müller WEG (2016b) Polyphosphate as a metabolic fuel in Metazoa: a foundational breakthrough invention for biomedical applications. Biotechnol J 11:11–30

    Article  CAS  PubMed  Google Scholar 

  • Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, Fardelonne P, Brazier M (2003) Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 65:35–42

    Article  CAS  PubMed  Google Scholar 

  • Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM, Wan Y (2010) PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11:503–516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Whitfield J (2006) Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How might they do it? Curr Opin Investig Drugs 7:349–359

    CAS  PubMed  Google Scholar 

  • Wiens M, Belikov SI, Kaluzhnaya OV, Adell T, Schröder HC, Perovic-Ottstadt S, Kaandorp JA, Müller WEG (2008) Regional and modular expression of morphogenetic factors in the demosponge Lubomirskia baicalensis. Micron 39:447–460

    Article  CAS  PubMed  Google Scholar 

  • Wiens M, Wang XH, Schloßmacher U, Lieberwirth I, Glasser G, Ushijima H, Schröder HC, Müller WEG (2010a) Osteogenic potential of bio-silica on human osteoblast-like (SaOS-2) cells. Calcif Tissue Intern 87:513–524

    Article  CAS  Google Scholar 

  • Wiens M, Wang XH, Schröder HC, Kolb U, Schloßmacher U, Ushijima H, Müller WEG (2010b) The role of biosilica in the osteoprotegerin/RANKL ratio in human osteoblast-like cells. Biomaterials 31:7716–7725

    Article  CAS  PubMed  Google Scholar 

  • Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Woo JT, Nakagawa H, Notoya M, Yonezawa T, Udagawa N, Lee IS, Ohnishi M, Hagiwara H, Nagai K (2004) Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull 27:504–509

    Article  CAS  PubMed  Google Scholar 

  • Xue Y, Xiao Y, Liu J, Karaplis AC, Pollak MR, Brown EM, Miao D, Goltzman D (2012) The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab 302:E841–E851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106–2111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zakharian E, Thyagarajan B, French RJ, Pavlov E, Rohacs T (2009) Inorganic polyphosphate modulates TRPM8 channels. PLoS ONE 4:e5404. doi:10.1371/journal.pone.0005404

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zerbini CA, McClung MR (2013) Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. Ther Adv Musculoskelet Dis 5:199–209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang S, Xiao Z, Luo J, He N, Mahlios J, Quarles LD (2009) Dose-dependent effects of Runx2 on bone development. J Bone Miner Res 24:1889–1904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

W.E.G. Müller is a holder of an ERC Advanced Investigator Grant (no. 268476 “BIOSILICA”) as well as of the two ERC Proof-of-Concept grants “Si-Bone-PoC” (no. 324564) and “MorphoVES-PoC” (No. 662486). This work was supported by grants from the European Commission (large-scale integrating project “BlueGenics” No. 266033 and project “Bio-Scaffolds” No. 604036), as well as the BiomaTiCS research initiative of the University Medical Center Mainz.

Author information

Authors and Affiliations

  1. ERC Advanced Investigator Group, Institute for Physiological Chemistry, University Medical Center of the Johannes Gutenberg University, Duesbergweg 6, 55128, Mainz, Germany

    Werner E. G. Müller, Xiaohong Wang & Heinz C. Schröder

  2. NanotecMARIN GmbH, Duesbergweg 6, 55128, Mainz, Germany

    Werner E. G. Müller, Xiaohong Wang & Heinz C. Schröder

Authors
  1. Werner E. G. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaohong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heinz C. Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Werner E. G. Müller .

Editor information

Editors and Affiliations

  1. ERC Advanced Investigator Group, Institute for Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

    Werner E. G. Müller

  2. ERC Advanced Investigator Group, Institute for Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

    Heinz C. Schröder

  3. ERC Advanced Investigator Group, Institute for Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

    Xiaohong Wang

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Müller, W.E.G., Wang, X., Schröder, H.C. (2017). New Target Sites for Treatment of Osteoporosis. In: Müller, W., Schröder, H., Wang, X. (eds) Blue Biotechnology. Progress in Molecular and Subcellular Biology(), vol 55. Springer, Cham. https://doi.org/10.1007/978-3-319-51284-6_6

Download citation

Publish with us

Policies and ethics

Search

Navigation